On the Record · Exact Sciences
Exact Sciences acquisitions, on the record
The businesses Exact Sciences bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Resolution Bioscience, Inc.Word for word“On September 12, 2023, we completed the acquisition of all of the outstanding capital stock of Resolution Bioscience, Inc. from Agilent Technologies, Inc.” 10-K for 2023 | acquisition | September 12, 2023 | — |
Oncotype DX Genomic Prostate Score test (GPS test) assets to MDxHealth SAWord for word“For example, in August 2022 we completed a divestiture of assets related to our Oncotype DX Genomic Prostate Score test ("GPS test") to MDxHealth SA ("MDxHealth").” 10-K for 2023 | divestiture | August 2022 | — |
OmicEra Diagnostics, GmbHWord for word“This was partially offset by amortization of the intangible assets acquired as part of our acquisition of OmicEra Diagnostics, GmbH in May 2022 and Resolution Bioscience in September 2023.” 10-K for 2023 | acquisition | May 2022 | — |
PreventionGenetics, LLCWord for word“As part of the acquisition of PreventionGenetics, LLC ("PreventionGenetics") in December 2021, we acquired a CLIA-certified and CAP-accredited DNA testing laboratory in Marshfield, Wisconsin.” 10-K for 2023 | acquisition | December 2021 | — |
Ashion Analytics, LLCWord for word“In April 2021, we began performing and selling the OncoExTra test, previously known as GEM ExTra, as a result of our acquisition of Ashion Analytics, LLC ("Ashion").” 10-K for 2023 | acquisition | April 2021 | — |
Thrive Earlier Detection CorporationWord for word“As a result of the acquisition of Thrive in January 2021, an additional $450.0 million would be payable in cash to Thrive's former shareholders upon the achievement of two discrete events, FDA approval and CMS coverage, for $150.0 million, and $300.0 million, respectively, in relation to the development and commercialization of a blood-based, multi-cancer early detection test.” 10-K for 2023 | acquisition | January 2021 | — |
Genomic Health, Inc.Word for word“This settlement agreement required us to pay $32.5 million, which was paid in October, 2023.” 10-K for 2023 | acquisition | — | — |
Oncotype DX Genomic Prostate Score test (GPS test) sold to MDxHealthWord for word“The income recorded for the year ended December 31, 2023 primarily relates to a $73.3 million contingent consideration gain and $3.1 million in additional consideration received from MDxHealth as a result of an amendment to the asset purchase agreement in August 2023.” 10-K for 2024 | divestiture | August 2023 | $73.3 million contingent consideration gain and $3.1 million in additional consideration |
Thrive Earlier Detection Corporation (Thrive)Word for word“As a result of the acquisition of Thrive in January 2021, an additional $450.0 million would be payable in cash to Thrive's former shareholders upon the achievement of two discrete events, FDA approval and CMS coverage, for $150.0 million, and $300.0 million, respectively, in relation to the development and commercialization of a blood-based, MCED test.” 10-K for 2024 | acquisition | January 2021 | an additional $450.0 million would be payable in cash to Thrive's former shareholders upon the achievement of two discrete events, FDA approval and CMS coverage, for $150.0 million, and $300.0 million, respectively |
Ashion Analytics, LLC (Ashion)Word for word“As a result of the acquisition of Ashion in April 2021, an additional $20.0 million would be payable in cash to Ashion's former shareholders upon the commercial launch, on or before the tenth anniversary of the acquisition of Ashion, of a test for MRD detection and/or treatment.” 10-K for 2024 | acquisition | April 2021 | an additional $20.0 million would be payable in cash to Ashion's former shareholders upon the commercial launch |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Goodwill from acquisitions |
|---|---|---|
| 2017-12-31 | $3 million | — |
| 2018-12-31 | $17.9 million | — |
| 2019-12-31 | $973.9 million | $1.19 billion |
| 2020-12-31 | $6.7 million | $30.4 million |
| 2021-12-31 | $499.7 million | — |
| 2022-12-31 | $14.7 million | — |
| 2023-12-31 | $52.4 million | — |
| 2024-12-31 | $0 | — |
| 2025-12-31 | $0 | — |
Deal filings since 2016
- 2026-03-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-03-23 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2025-11-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-01-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-04-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-03-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-06-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-11-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-10-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-10-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-02-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-11-08 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2019-07-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-07-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-03-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-08-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-06-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-01-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-12-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-06-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-04-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-08-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Exact Sciences’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-13. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.